What's Inside
Ozempic, a medication used to treat type 2 diabetes, is gaining strong momentum in the pharmaceutical market due to its ability to manage blood sugar levels and promote weight loss. The increased adoption of Ozempic and other drugs in the GLP-1 drug class reflects a broader consumer shift toward prioritizing health and wellness.
We dive into the implications of widespread GLP-1 drug use on US retail, including the impacts on sectors such as grocery and apparel.
Companies mentioned in this report include: Hershey, Lululemon Athletica, Mondelēz International, NIKE, PepsiCo, Walmart
Other relevant research:
- Weinswig’s Weekly: Health Is Wealth
- Market Navigator: US Apparel and Footwear Retailing—After the Bounce, What’s Next?
- Generative AI for US Retail Pharmacies and Healthcare: Satisfying Customers through Automation and Personalization
- Visit the Coresight Research Food, Grocery and CPG Retail Hub to explore sector data, reports and company profiles.
You are currently viewing a preview of this report.
Please select an access option to view the full report. Hide Options - Show Options +
This document was generated for